CLDX Aug 2024 40.000 call
- Zacks
Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet
The mean of analysts' price targets for Celldex (CLDX) points to an 87.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- GlobeNewswire
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
HAMPTON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell. Mast cells are believed to play an impo
- Zacks
Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade
The consensus price target hints at a 67.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
